Amneal Pharmaceuticals (AMRX) Receivables - Net (2017 - 2026)

Amneal Pharmaceuticals' Receivables - Net history runs 10 years deep, the most recent figure standing at $413000.0 for Q1 2026.

• On a quarterly basis, Receivables - Net fell 99.97% year-over-year to $413000.0 in Q1 2026; TTM through Mar 2026 was $413000.0, a 99.97% decrease from a year earlier, with the FY2025 full-year figure at $413000.0, down 7.61% from the prior year.
• Receivables - Net held at $413000.0 in Q1 2026 per AMRX's latest filing, from $413000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $1.4 billion in Q3 2025 and bottomed at $413000.0 in Q4 2025.
• The 5-year median for Receivables - Net is $1.0 billion (2022), against an average of $789.4 million.
• Across the five-year window, Receivables - Net soared 126182.3% in 2023 and tumbled 99.97% in 2026, its largest moves.
• Year by year, Receivables - Net stood at $486000.0 in 2022, then surged by 126182.3% to $613.7 million in 2023, then slumped by 99.93% to $447000.0 in 2024, then declined by 7.61% to $413000.0 in 2025, then changed by 0.0% to $413000.0 in 2026.
• Per Business Quant, the three latest AMRX Receivables - Net figures stand at $413000.0 (Q1 2026), $413000.0 (Q4 2025), and $1.4 billion (Q3 2025).